New Insights into Cyclobutenone Rearrangements: A Total Synthesis of the Natural ROS-Generating Anti-Cancer Agent Cribrostatin 6
作者:Mubina Mohamed、Théo P. Gonçalves、Richard J. Whitby、Helen F. Sneddon、David C. Harrowven
DOI:10.1002/chem.201102263
日期:2011.12.2
Aryl‐ and heteroarylcyclobutenone rearrangements proceed in excellent yield under continuous‐flow conditions. The former shows a Hammett correlation with σI providing strong evidence that electrocyclisation is the rate‐determining step and has a late transition state. The reaction has been modelled by using DFT and CCSD(T) methods, with the latter giving excellent correlation with the experimental
[EN] METTL3 INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE METTL3
申请人:STORM THERAPEUTICS LTD
公开号:WO2022074379A1
公开(公告)日:2022-04-14
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.